News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Senesco Technologies, Inc. (SNT) Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com


2/11/2013 9:22:34 AM

NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Senesco Technologies, Inc. (OTC: SNTI) announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing.

LINK: www.retailinvestorconferences.com > red "register/ watch event now" button

Senesco's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Senesco Technologies, Inc.

Senesco (SNTI) is focused on developing cancer therapeutics. Its approach is based on its discovery that eIF5A, a novel pathway, has the ability to regulate programmed cell death and cell survival. Programmed cell death, or apoptosis, is a natural process that is used by the body to eliminate defective or diseased cells. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases

Senesco is sponsoring a clinical study to evaluate its first therapeutic candidate SNS01-T in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma. SNS01-T targets B-cell cancers and selectively induces apoptosis by modulating eukaryotic translation initiation factor 5A (eIF5A).Patient cohort 1 has completed and currently two of the planned three patients in cohort 2 have completed dosing. No drug-related serious adverse events or disease limiting toxicities have been recorded to date..

Senesco has already partnered its technology platform with leading-edge companies engaged in agricultural biotechnology and biofuels development, and is entitled to earn research and development milestones and royalties if its technology is incorporated into its partners' products.

About SNS01-T

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, the Mary Babb Randolph Cancer Center in Morgantown, WV, and the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, NJ. http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire, and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

SOURCE Senesco Technologies, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES